M
Mesoblast Limited D
D
MESO
16.360
USD
-0.57
(-3.37%)
مغلق
حجم التداول
7,617
الربح لكل سهم
-1
العائد الربحي
-
P/E
-17
حجم السوق
2,093,138,122
الأخبار المقالات
العنوان: Mesoblast Limited
القطاع: Healthcare
الصناعة: Biotechnology
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.